Lars Fruergaard Jørgensen, CEO of Novo Nordisk, speaks during an interview in New York on Aug. 10, 2022.Novo Nordisk's top executive is slated to face a Senate grilling on Tuesday over the high prices of the company's weight loss drug Wegovy and diabetes treatment Ozempic, as demand for both injections soars in the U.S. Novo Nordisk CEO Lars Fruergaard Jørgensen will testify at a Senate Health, Education, Labor and Pensions Committee hearing at 10 a.m. ET on Tuesday in Washington, D.C. It comes roughly five ...

Key TakeawaysNovo Nordisk CEO Lars Fruergaard Jorgensen will testify Tuesday before a Senate panel looking into the drug maker's pricing of weight-loss drugs Wegovy and Ozempic.The committee accused the company of charging "outrageously high prices" for the treatments.Jorgensen has defended the costs, and said most Americans with insurance pay $25 a month for Wegovy. Novo Nordisk's (NVO) U.S.-listed shares lost ground Monday, a day before a Senate hearing on the costs of the company's popular weight-loss dr ...

Lars Fruergaard Jørgensen, President and CEO of Novo Nordisk A/S NVO, is set to face tough questions from the U.S. lawmakers regarding the steep prices of the company’s diabetes and weight-loss drugs, including Ozempic and Wegovy.The United States Senate Committee on Health, Education, Labor, and Pensions (HELP) hearing is scheduled for Tuesday, September 24th.Leading the charge is Senator Bernie Sanders, chair of the Senate committee, who has been outspoken about the high cost of these medicines.Also Read: ...

Shares of Novo Nordisk (NVO) lost 5.5% on Friday after the company announced top-line data from a mid-stage study evaluating the safety and efficacy of its investigational candidate, monlunabant (formerly INV-202), to treat obesity. The stock price is likely to have declined as the efficacy and safety results failed to impress the investors.Monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist, was added to Novo Nordisk’s clinical pipeline following the acquisition of Inversago Pha ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.In the pharmaceutical world, it's never good for a company to stumble in a hot therapeutic area, especially if it has some determined rivals competing in the same segment.That was the dynamic behind Wegovy and Ozempic developer Novo Nordisk's (NVO -5.46%) Friday stumble on the stock exchange --following its latest news from the lab -- and the gains enjoyed that day by up-and-coming Viki ...

Key TakeawaysNovo Nordisk's U.S.-listed shares lost ground Friday after a Phase 2a trial of the pharmaceutical firm’s latest obesity treatment showed less effectiveness in higher doses.Based on the results, Novo Nordisk said it would be initiating a larger Phase 2b study next year.Novo Nordisk shares were down over 5% in intraday trading Friday, though even with Friday's losses, they've gained more than 22% since the start of the year. Novo Nordisk's (NVO) U.S.-listed shares lost ground Friday after a study ...

Novo Nordisk A/S (NVO) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) adopted a positive opinion, recommending a label update of its blockbuster weekly injection for chronic weight management, Wegovy (semaglutide 2.4 mg).The CHMP has recommended a label update for Wegovy that reflects reduced heart failure symptoms, improved physical limitations and exercise function in people with obesity-related heart failure with preserved ejection fraction (HFpEF), ...

Novo Nordisk (NVO) shares have lost 5% in the past three months, which translates to approximately $29 billion in market value, against the industry’s growth of 2.6%. NVO has also underperformed in the sector and the S&P 500 in the past three months, as seen in the chart below.NVO Stock Underperforms the Industry, Sector & the S&P 500Image Source: Zacks Investment ResearchThe dip in the stock price was primarily observed after the company faced a major setback in July when the FDA rejected its regulatory fi ...

Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc. announced in August 2023 [Link]. The trial investigated the efficacy and safety of a once-daily 10 mg, 20 mg and 50 mg dose of monlunabant compared to placebo on body weight after 16 weeks in 243 people with obesity a ...

Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function Wegovy® (semaglutide 2.4 mg) is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise function in people with obesity-related heart failure with preserved ejection fraction (HFpEF).The positive opinion is based on results from the STEP HFpEF and STEP H ...